RetroSPECT: Gallium-67 as a Long-Lived Imaging Agent for Theranostics | ||
| Asia Oceania Journal of Nuclear Medicine and Biology | ||
| مقاله 1، دوره 9، شماره 1، فروردین 2021، صفحه 1-8 اصل مقاله (1.11 M) | ||
| نوع مقاله: Special Contribution | ||
| شناسه دیجیتال (DOI): 10.22038/aojnmb.2020.51714.1355 | ||
| نویسندگان | ||
| Dale L Bailey* 1، 2، 3؛ Dhanusha Sabanathan4؛ Alireza Aslani1، 3؛ Douglas H Campbell4؛ Bradley Walsh4؛ Nigel A Lengkeek5 | ||
| 1Department of Nuclear Medicine, Royal North Shore Hospital, Sydney, Australia | ||
| 2Sydney Vital Translational Cancer Research Centre, Sydney, Australia | ||
| 3Faculty of Medicine & Health, University of Sydney, Sydney, Australia | ||
| 4GlyTherix Ltd, Sydney, Australia | ||
| 5Biosciences, Australian Nuclear Science & Technology Organisation (ANSTO), Sydney, Australia | ||
| چکیده | ||
| A limitation to the wider introduction of personalised dosimetry in theranostics is the relative paucity of imaging radionuclides with suitable physical and chemical properties to be paired with a long-lived therapeutic partner. As most of the beta-emitting therapeutic radionuclides emit gamma radiation as well they could potentially be used as the imaging radionuclide as well as the therapeutic radionuclide. However, the downsides are that the beta radiation will deliver a significant radiation dose as part of the treatment planning procedure, and the gamma radiation branching ratio is often quite low. Gallium-67 has been in use in nuclear medicine for over 50 years. However, the tremendous interest in gallium imaging in theranostics in recent times has focused on the PET radionuclide gallium-68. In this article it is suggested that the longer-lived gallium-67, which has desirable characteristics for imaging with the gamma camera and a suitably long half-life to match biological timescales for drug uptake and turnover, has been overlooked, in particular, for treatment planning with radionuclide therapy. Gallium-67 could also allow non-PET facilities to participate in theranostic imaging prior to treatment or for monitoring response after therapy. Gallium-67 could play a niche role in the future development of personalised medicine with theranostics. | ||
| کلیدواژهها | ||
| Theranostics؛ Gallium-67؛ Precision Medicine | ||
| مراجع | ||
|
1. Hertz S, Roberts A. Radioactive iodine in the study of thyroid physiology; the use of radioactive iodine therapy in hyperthyroidism. J Am Med Assoc. 1946; 131:81-6.
2. Langbein T, Weber WA, Eiber M. Future of Theranostics: An Outlook on Precision Oncology in Nuclear Medicine. J Nucl Med. 2019; 60(Suppl 2):13S-9S.
3. Hicks RJ, Jackson P, Kong G, Ware RE, Hofman MS, Pattison DA, et al. (64)CuSARTATE PET Imaging of Patients with Neuroendocrine Tumors Demonstrates High Tumor Uptake and Retention, Potentially Allowing Prospective Dosimetry for Peptide Receptor Radionuclide Therapy. J Nucl Med. 2019; 60(6):777-85.
4. Bailey DL, Schembri GP, Willowson KP, Hedt A, Lengyelova E, Harris M. A Novel Theranostic Trial Design Using 64Cu/67Cu with Fully 3D Pre-Treatment Dosimetry. J Nucl Med. 2019; 60(Suppl. 1):204 (Abstract).
5. Edwards CL, Hayes RL. Tumor scanning with 67Ga citrate. J Nucl Med. 1969; 10(2):103-5.
6. Siegel JA, Thomas SR, Stubbs JB, Stabin MG, Hays MT, Koral KF, et al. MIRD pamphlet no. 16: Techniques for quantitative radiopharmaceutical biodistribution data acquisition and analysis for use in human radiation dose estimates. J Nucl Med. 1999; 40(2):37S-61S.
7. ARSAC. Notes for Guidance on the Clinical Administration of Radiopharmaceuticals and Use of Sealed Radioactive Sources. London: Administration of Radioactive Substances Advisory Committee, UK; 1998 December, 1998.
8. Synowiecki MA, Perk LR, Nijsen JFW. Production of novel diagnostic radionuclides in small medical cyclotrons. EJNMMI Radiopharm Chem. 2018; 3(1):3.
9. Tárkányi F, Takács S, Ditrói F, Hermanne A, Sonck M, Shubin Y. Excitation functions of deuteron induced nuclear reactions on natural zinc up to 50 MeV. Nuclear Instruments and Methods in Physics Research Section B: Beam Interactions with Materials and Atoms. 2004; 217(4):531-50.
10. Agency IAE. Cyclotron Produced Radionuclides: Physical Characteristics and Production Methods. Vienna: IAEA; 2009.
11. Matzapetakis M, Kourgiantakis M, Dakanali M, Raptopoulou CP, Terzis A, Lakatos A, et al. Synthesis, pH-Dependent Structural Characterization, and Solution Behavior of Aqueous Aluminum and Gallium Citrate Complexes. Inorganic Chemistry. 2001; 40(8):1734-44.
12. Ščasnár V, van Lier JE. The use of SEP-PAK Sl cartridges for the preparation of gallium chloride from the citrate solution. European Journal of Nuclear Medicine. 1993; 20(3):273.
13. Morfin J-F, Tóth É. Kinetics of Ga (NOTA) Formation from Weak Ga-Citrate Complexes. Inorganic Chemistry. 2011; 50(20):10371-8.
14. Sundberg MW, Meares CF, Goodwin DA, Diamanti CI. Chelating agents for the binding of metal ions to macromolecules. Nature. 1974; 250(5467):587-8.
15. Sundberg MW, Meares CF, Goodwin DA, Diamanti CI. Selective binding of metal ions to macromolecules using bifunctional analogs of EDTA. Journal of Medicinal Chemistry. 1974; 17(12):1304-7.
16. Hnatowich D, Layne W, Childs R, Lanteigne D, Davis M, Griffin T, et al. Radioactive labeling of antibody: a simple and efficient method. Science. 1983; 220(4597):613-5.
17. Koizumi M, Endo K, Watanabe Y, Saga T, Sakahara H, Konishi J, et al. Immunoscintigraphy and Pharmacokinetics of Indium-111-labeled ZME-018 Monoclonal Antibody in Patients with Malignant Melanoma. 1988; 79(8):973-81.
18. Rainsbury RM, Westwood JH, Coombes RC, Neville AM, Ott RJ, Kalirai TS, et al. Loction of metastatic breast carcinoma by a monoclonal antibody chelate labelled with Indium-111. The Lancet. 1983; 322 (8356):934-8.
19. Scheinberg D, Strand M, Gansow O. Tumor imaging with radioactive metal chelates conjugated to monoclonal antibodies. 1982; 215(4539):1511-3.
20. Ward MC, Roberts KR, Westwood JH, Coombes RCC, McCready VR. The Effect of Chelating Agents on the Distribution of Monoclonal Antibodies in Mice. 1986; 27(11):1746-50.
21. Blower PJ. A nuclear chocolate box: the periodic table of nuclear medicine. Dalton Transactions. 2015; 44(11):4819-44.
22. Brandt M, Cardinale J, Aulsebrook ML, Gasser G, Mindt TL. An Overview of PET Radiochemistry, Part 2: Radiometals. 2018; 59(10):1500-6.
23. Cutler CS, Hennkens HM, Sisay N, HuclierMarkai S, Jurisson SS. Radiometals for Combined Imaging and Therapy. Chemical Reviews. 2013; 113(2):858-83.
24. Price EW, Orvig C. Matching chelators to radiometals for radiopharmaceuticals. Chemical Society Reviews. 2014; 43(1):260-90.
25. Spang P, Herrmann C, Roesch F. Bifunctional Gallium-68 Chelators: Past, Present, and Future. Seminars in Nuclear Medicine. 2016; 46(5):373-94.
26. Velikyan I, Maecke H, Langstrom B. Convenient Preparation of 68Ga-Based PETRadiopharmaceuticals at Room Temperature. Bioconjugate Chemistry. 2008; 19(2):569-73.
27. Evers A, Hancock RD, Martell AE, Motekaitis RJ. Metal ion recognition in ligands with negatively charged oxygen donor groups. Complexation of iron (III), gallium (III), indium (III), aluminium (III), and otherhighly charged metal ions. Inorganic Chemistry. 1989; 28(11):2189-95.
28. Boros E, Holland JP. Chemical aspects of metal ion chelation in the synthesis and application antibody-based radiotracers. 2018; 61(9):652-71.
29. Othman MFb, Verger E, Costa I, Tanapirakgul M, Cooper MS, Imberti C, et al. In vitro cytotoxicity of Auger electron-emitting [ 67Ga] Ga-trastuzumab. Nuclear Medicine and Biology. 2020; 80-81:57-64.
30. Tsionou MI, Knapp CE, Foley CA, Munteanu CR, Cakebread A, Imberti C, et al. Comparison of macrocyclic and acyclic chelators for gallium-68 radiolabelling. RSC Advances. 2017; 7(78):49586-99.
31. Acchione M, Kwon H, Jochheim CM, Atkins WM. Impact of linker and conjugation chemistry on antigen binding, Fc receptor binding and thermal stability of model antibody-drug conjugates. MAbs. 2012; 4(3):362-72.
32. Alley SC, Benjamin DR, Jeffrey SC, Okeley NM, Meyer DL, Sanderson RJ, et al. Contribution of Linker Stability to the Activities of Anticancer Immunoconjugates. Bioconjugate Chemistry. 2008; 19(3):759-65.
33. Koizumi M, Endo K, Kunimatsu M, Sakahara H, Nakashima T, Kawamura Y, et al. 67Galabeled Antibodies for Immunoscintigraphy and Evaluation of Tumor Targeting of DrugAntibody Conjugates in Mice. 1988; 48(5):1189-94.
34. Forte N, Chudasama V, Baker JR. Homogeneous antibody-drug conjugates via siteselective disulfide bridging. Drug Discovery Today: Technologies. 2018; 30:11-20.
35. Tsuchikama K, An Z. Antibody-drug conjugates: recent advances in conjugation and linker chemistries. Protein & Cell. 2018; 9(1):33-46.
36. Van Berkel SS, van Delft FL. Enzymatic strategies for (near) clinical development of antibody-drug conjugates. Drug Discovery Today: Technologies. 2018; 30:3-10.
37. Morais M, Ma MT. Site-specific chelatorantibody conjugation for PET and SPECT imaging with radiometals. Drug Discovery Today: Technologies. 2018; 30:91-104.
38. Truong Q, Justiniano IO, Nocon AL, Soon JT, Wissmueller S, Campbell DH, et al. Glypican- 1 as a Biomarker for Prostate Cancer: Isolation and Characterization. J Cancer. 2016; 7(8):1002-9.
39. Lund ME, Campbell DH, Walsh BJ. The Role of Glypican-1 in the Tumour Microenvironment. Adv Exp Med Biol. 2020; 1245:163-76.
40. Yeh MC, Tse BWC, Fletcher NL, Houston ZH, Lund M, Volpert M, et al. Targeted beta therapy of prostate cancer with (177)Lulabelled Miltuximab(R) antibody against glypican-1 (GPC-1). EJNMMI Res. 2020; 10(1):46.
41. Campbell DH, Sabanathan D, Gurney H, Gillatt D, Trifunovic M, Poursoultan P, et al. Outcomes of the miltuximab first in human trial and proposed study design for a phase I trial 89Zr/177Lu theranostic trial. J Clin Oncol. 2019; 37(7_suppl).
42. Bailey DL, Hennessy TM, Willowson KP, Henry EC, Chan DLH, Roach PJ. In Vivo Quantification of 177Lu with Planar WholeBody and SPECT/CT Gamma Camera Imaging. Eur J Nucl Med Mol Imag Physics. 2015; 2:20.
43. Toriihara A, Daisaki H, Yamaguchi A, Yoshida K, Isogai J, Tateishi U. Applying standardized uptake values in gallium-67-citrate singlephoton emission computed tomography/ computed tomography studies and their correlation with blood test results in representative organs. Nuclear Medicine Communications. 2018; 39(8):720-4.
44. Ryu H, Meikle SR, Willowson KP, Eslick EM, Bailey DL. Performance evaluation of quantitative SPECT/CT using NEMA NU 2 PET methodology. Phys Med Biol. 2019; 64(14):145017.
45. Wang G, Qi J. PET Image Reconstruction Using Kernel Method. IEEE Trans Med Imaging. 2015; 34(1):61–71.
46. Deidda D, Karakatsanis NA, Robson PM, Tsai Y-J, Efthimiou N, Thielemans K, et al. Hybrid PET-MR list-mode kernelized expectation maximization reconstruction. Inverse Prob. 2019; 35(4):044001.
47. Zweit J, Sharma H, Downey S. Production of Gallium-66, A Short-lived, Positron Emitting Radionuclide Appl Radiat Isot. 1987; 38(7):499-501.
48. Bailey DL. Thirty years from now: future physics contributions in nuclear medicine. Eur J Nucl Med Mol Imag Physics. 2014; 1(4):1-8. | ||
|
آمار تعداد مشاهده مقاله: 1,073 تعداد دریافت فایل اصل مقاله: 886 |
||